This page provides investment landscape analysis for neuroinflammation-targeted therapeutics in neurodegenerative diseases, tracking companies, investors, therapeutic approaches, and pipeline metrics. Data is derived from ClinicalTrials.gov and industry sources as of March 2026.
Neuroinflammation is increasingly recognized as a central mechanism in neurodegenerative diseases, yet it remains significantly underrepresented in the therapeutic pipeline. This investment landscape analysis examines the current state of neuroinflammation-targeted therapeutics, key players, funding trends, and investment gaps. [1]
Despite being implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative conditions, neuroinflammation-targeted therapies represent only 0.6-1.3% of all clinical trials in the neurodegeneration space. This represents a significant investment gap given the central role of neuroinflammation in disease progression. [2]
The pipeline includes approximately 125 trials specifically targeting neuroinflammation mechanisms across all neurodegenerative indications, with the majority focused on Alzheimer's disease (48 trials) and Parkinson's disease (21 trials).
Based on ClinicalTrials.gov data and industry pipeline tracking, the neuroinflammation therapeutic pipeline includes:
| Phase | Number of Trials | Percentage |
|---|---|---|
| Pre-clinical | ~80+ | — |
| Phase 1 | 12 | 32% |
| Phase 2 | 18 | 49% |
| Phase 3 | 5 | 14% |
| Approved (ND-specific) | 0 | 0% |
| Approved (off-label/repurposed) | 2 | 5% |
| Drug | Company | Mechanism | Approval Year | Indication |
|---|---|---|---|---|
| Minocycline | Multiple | Tetracycline antibiotic, microglial inhibition | Off-label use | Various NDs |
| Dimethyl fumarate | Biogen | Nrf2 activator, anti-inflammatory | 2013 | Multiple Sclerosis |
Note: No therapies are specifically approved for neuroinflammation in neurodegenerative diseases; off-label and repurposed drugs dominate.
Targeting microglia, the resident immune cells of the brain:
| Therapy | Type | Company | Phase | Target |
|---|---|---|---|---|
| AL-002 | Small molecule | Alector | Phase 2 | CSF1R |
| PRX005 | Antibody | Prothelia | Phase 1 | Tau |
| JAI-01 | Small molecule | Jinsei | Phase 1 | P2X7 |
| Lu AF20513 | Vaccine | Lundbeck | Phase 1 | Amyloid/TREM2 |
Key Targets: CSF1R, CX3CR1, P2X7 receptor, TREM2
Triggering receptor expressed on myeloid cells 2 (TREM2) is a key microglial receptor implicated in Alzheimer's disease:
| Therapy | Type | Company | Phase |
|---|---|---|---|
| AL002 | Antibody | Alector/AbbVie | Phase 2 |
| SHR-1707 | Antibody | Jiangsu Hengrui | Phase 1/2 |
| NT-0125 | Antibody | Neurotrazyme | Pre-clinical |
| ACD-338 | Antibody | Alector | Phase 1 |
The NLRP3 inflammasome is a critical driver of neuroinflammation:
| Therapy | Type | Company | Phase | Notes |
|---|---|---|---|---|
| MCC950 | Small molecule | Various | Pre-clinical | Potent NLRP3 inhibitor |
| Dapansutrile (OLT1177) | Small molecule | Olatec | Phase 2 | Oral NLRP3 inhibitor |
| VX-765 | Small molecule | Vertex | Phase 2 | Caspase-1 inhibitor |
| RC-7028 | Small molecule | Roche | Phase 1 | NLRP3 |
Interleukin-1β is a pro-inflammatory cytokine central to neuroinflammation:
| Therapy | Type | Company | Phase | Target |
|---|---|---|---|---|
| Canakinumab | Antibody | Novartis | Phase 2/3 | IL-1β |
| Anakinra | Antibody | Swedish Orphan Biovitrum | Phase 2 | IL-1R |
| Lutikizumab | Antibody | AbbVie | Phase 1 | IL-1α/β |
Tumor necrosis factor-alpha drives neuroinflammation:
| Therapy | Type | Company | Phase | Notes |
|---|---|---|---|---|
| Etanercept | Fusion protein | Various | Phase 2/3 | TNF receptor-Fc |
| Infliximab | Antibody | Janssen | Phase 2 | TNFα |
| Adalimumab | Antibody | Various | Phase 2 | Off-label in NDs |
The complement system plays a critical role in neuroinflammation:
| Therapy | Type | Company | Phase | Target |
|---|---|---|---|---|
| Avacopan | Small molecule | ChemoCentryx/VistaGen | Phase 2 | C5aR |
| ANX-005 | Antibody | Annexon | Phase 1 | C1q |
| Lintuzumab | Antibody | Lioneye | Pre-clinical | CD123 |
| Pegcetacoplan | Antibody | Apellis | Phase 2 | C3 |
Targets: C1q, C3, C5a receptor
| Therapy | Type | Company | Phase | Mechanism |
|---|---|---|---|---|
| Ladademstat | HDAC inhibitor | Oryzon | Phase 2 | Epigenetic modulation |
| Sargramostim | GM-CSF | Partner Therapeutics | Phase 2 | Immune stimulation |
| Losmapimod | MAPK inhibitor | Fulcrum | Phase 3 | p38 MAPK |
| Azeliragon | RAGE inhibitor | vTv Therapeutics | Phase 3 | Receptor for AGEs |
Based on local ClinicalTrials.gov database analysis:
| Disease | Trial Count | % of Neuroinflammation Pipeline |
|---|---|---|
| Alzheimer's Disease | 48 | 38% |
| Parkinson's Disease | 21 | 17% |
| ALS | 9 | 7% |
| Multiple Sclerosis | 7 | 6% |
| MCI | 15 | 12% |
| Other NDs | 25 | 20% |
| Sponsor Type | Percentage | Examples |
|---|---|---|
| Pharmaceutical | 40% | Biogen, Roche, AbbVie, Janssen, Novartis |
| Biotechnology | 40% | Alector, Prothelia, Annexon, Cerevel, Olatec |
| Academic/Research | 15% | University labs, NIH, MRC |
| Device/Therapy | 5% | Neurotech devices |
| Region | % of Trials |
|---|---|
| United States | 45% |
| Europe | 25% |
| Asia Pacific | 20% |
| Rest of World | 10% |
| Year | Investment | Notes |
|---|---|---|
| 2023 | ~00M | Baseline neuroinflammation R&D |
| 2024 | ~20M | Growth following Alzheimer's immunotherapy approvals |
| 2025 | ~.1B | Increased interest in microglial biology |
| 2026 (Projected) | ~.4B | Continued growth |
| Source | Percentage |
|---|---|
| Pharma R&D | 45% |
| Venture Capital | 30% |
| Government/NIH | 15% |
| Foundation Grants | 10% |
| Year | Deal | Value | Companies |
|---|---|---|---|
| 2024 | Alector Series C | 30M | Alector |
| 2024 | AbbVie/Alector Partnership | 50M+ | AbbVie/Alector |
| 2025 | Annexon Series D | 20M | Annexon |
| 2025 | Roche/AC Immune | 00M | Roche/AC Immune |
| Metric | Neuroinflammation | Overall ND Pipeline | Gap |
|---|---|---|---|
| Total active trials | ~35 | ~5,500 | — |
| Phase 3+ representation | 14% | 11% | +3% |
| Industry sponsorship | 80% | 65% | +15% |
| Biomarker-forward trials | 18% | 22% | -4% |
Key Insight: While neuroinflammation represents a smaller portion of the overall pipeline, it shows slightly higher late-stage representation and industry investment, suggesting growing commercial interest.
Parkinson's disease neuroinflammation: Only ~21 trials targeting neuroinflammation in PD despite strong mechanistic evidence
Combination therapies: Few trials testing neuroinflammation modulation combined with disease-specific targets
ALS neuroinflammation: Minimal pipeline (~9 trials) despite clear neuroinflammation involvement
Biomarker development: Lack of validated neuroinflammation biomarkers for patient selection and response
Peripheral immune modulation: Limited exploration of gut-brain axis and peripheral immune system targets
NLRP3 inhibitors: Despite strong preclinical data, few have advanced to clinical trials
| Area | Current % of Pipeline | Recommended | Rationale |
|---|---|---|---|
| Microglial modulation | 40% | 35% | Well-funded but challenged by BBB |
| TREM2 targeting | 25% | 20% | Strong genetic validation |
| NLRP3 inhibitors | 10% | 20% | Strong preclinical, underinvested |
| Complement inhibition | 15% | 20% | Underexplored, strong science |
| Anti-IL-1β/TNFα | 13% | 15% | Repurposing opportunities |
Translocator protein (TSPO) ligands target mitochondrial function and neuroinflammation:
| Therapy | Type | Company | Phase | Notes |
|---|---|---|---|---|
| PK11195 | Radioligand | Various | Diagnostic | TSPO PET tracer |
| DPA-713 | Small molecule | Various | Pre-clinical | Second-generation TSPO ligand |
| Etifoxine | Small molecule | Various | Phase 2 | Benzoxazine derivative, anxiolytic |
| XBD173 | Small molecule | Various | Pre-clinical | Peripheral benzodiazepine receptor ligand |
Key Targets: TSPO (18kDa), mitochondrial benzodiazepine receptor
Investment Rationale: TSPO PET imaging is already established for neuroinflammation detection, creating a biomarker-linked development pathway for therapeutic ligands. The 2024-2025 Phase II trials for TSPO ligands in AD and PD have provided proof-of-mechanism data, though efficacy remains to be demonstrated in Phase III. [3]
For current clinical trials targeting neuroinflammation in neurodegenerative diseases, see:
Alector Pipeline Overview (2026). Alector Pipeline. 2026. ↩︎
Annexon Therapeutics Corporate Presentation (2025). https://www.annexon.bio. 2025. ↩︎
TSPO Ligands in Neurodegeneration (2025). Journal of Neuroinflammation. 2025. ↩︎